Dynavax Technologies Corp. (DVAX), which achieved record revenue for its lead product HEPLISAV-B in 2024, is focused on driving significant top-line growth in 2025 as it continues to establish HEPLISAV-B as the market share leader in the expanding hepatitis B vaccine market in the U.S.
HEPLISAV-B, given in 2 doses, 1 month apart, is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. CpG 1018 is the adjuvant used in HEPLISAV-B to provide an increased vaccine immune response.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com